CD274 and non-small cell lung carcinoma: When focusing on inclusion of two or more comparators for PD-(L)1 inhibitors, this was often related to both the TPS (PD-L1 expression of ≥ 1%; 0–49%; or ≥ 50%) and squamous or non-squamous NSCLC status.